Abstract: Cancer is an important disease which jeopardizes people's health, and also one of the important causes of human death. With the progress of technology, the treatments of cancer are no longer limited to the surgical treatment, chemotherapy and traditional radiotherapy. Endocrine therapy, immunotherapy, targeted therapy and other novel therapeutic methods have also been developed. Although there are many therapies for cancer, the effect of cancer treatment is unsatisfactory. Poor therapeutic effect of cancer treatment is associated with difficulty of early diagnosis, deficiency of remedy and some other factors. Moreover, the emergence of resistance to the tumor treatment has also brought great obstacles to cancer therapy. In recent years, many studies have shown that there is a close relationship between high mobility group protein B1 (HMGB1) and tumor chemotherapy resistance. Some researchers have found that HMGB1 can promote tumor therapy resistance by participating in cell autophagy, DNA damage repair, resistance to cell apoptosis, promotion of cell proliferation and angiogenesis, enhancement of immune escape and inflammation. In this paper, the recent research progress of the correlation between HMGB1 and tumor therapy resistance were reviewed.

Key words: HMGB1, Neoplasm, Therapy resistance